KalVista Pharmaceuticals (KALV) Accumulated Expenses (2016 - 2024)
Historic Accumulated Expenses for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $18.9 million.
- KalVista Pharmaceuticals' Accumulated Expenses changed N/A to $18.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.9 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is N/A changed from last year.
- Latest data reveals that KalVista Pharmaceuticals reported Accumulated Expenses of $18.9 million as of Q4 2024.
- KalVista Pharmaceuticals' Accumulated Expenses' 5-year high stood at $18.9 million during Q4 2024, with a 5-year trough of $4.9 million in Q1 2020.
- In the last 4 years, KalVista Pharmaceuticals' Accumulated Expenses had a median value of $9.2 million in 2023 and averaged $10.0 million.
- Within the past 5 years, the most significant YoY rise in KalVista Pharmaceuticals' Accumulated Expenses was 4480.17% (2020), while the steepest drop was 340.0% (2020).
- Over the past 4 years, KalVista Pharmaceuticals' Accumulated Expenses (Quarter) stood at $6.9 million in 2020, then fell by 23.86% to $5.3 million in 2021, then skyrocketed by 121.51% to $11.7 million in 2023, then skyrocketed by 61.75% to $18.9 million in 2024.
- Its last three reported values are $18.9 million in Q4 2024, $15.4 million for Q4 2024, and $10.4 million during Q3 2024.